Impact of Immediate Cisplatin/Gemcitabine Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer: an Open-label, Single-arm, Prospective Trial
Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall. Immediate systemic chemotherapy post-surgery aims to eliminate microlesions promptly and minimize recurrence risk, yet its safety and efficacy require further exploration. This prospective, single-arm study delves into evaluating the efficacy and safety of immediate postoperative systemic chemotherapy in patients with suspected high-risk non-muscle-invasive bladder cancer.
• Patients with a history and cystoscopy results indicating high-risk NMIBC:
‣ High-grade T1
⁃ Any recurrent high-grade Ta
⁃ High-grade Ta \& Tumor diameter greater than 3 cm or multifocal
⁃ Any CIS
⁃ Any BCG failure in patients with high-grade disease
⁃ Any variant histology
⁃ Any LVI
⁃ Any high-grade prostatic urethral involvement
• Patients in generally good condition with a follow-up period of 2 years